ZAMMSA Achieves 70% Availability of Laboratory Products
The Zambia Medicines and Medical Supplies Agency (ZAMMSA) has reported a significant increase in the availability of laboratory commodities, reaching an impressive 70% stock availability in the past week.
Bradley Chingobe, ZAMMSA’s Senior Manager for Corporate Communications, highlighted that the availability of laboratory commodities at the ZAMMSA central warehouse had previously fluctuated between 50 to 55% since 2023. This marks the first time the agency has achieved a notable 70% stock level.
Mr Chingobe stated that this milestone reflects ZAMMSA’s dedication to ensuring access to essential medical supplies, specifically laboratory consumables and reagents.
He emphasised the importance of these products for conducting diagnostic tests across healthcare facilities nationwide.
The availability of these commodities enables healthcare professionals to accurately diagnose and determine appropriate treatments for various diseases and conditions affecting the Zambian population.
Significantly, ZAMMSA has also seen a marked improvement in the availability of haematology reagents, which are crucial for the efficient operation of laboratory machines and enhancing diagnostic processes.
Mr Chingobe attributed this success to ZAMMSA’s streamlined procurement strategy and the support from cooperating partners, which have facilitated the effective distribution of haematology products nationwide through a comprehensive last-mile distribution effort.
Furthermore, he reported that current stock levels for laboratory products, including haematology reagents and HIV testing kits, are at 100%, while biochemistry commodities are at 79%, sufficient to meet demand for the next five months.
ZAMMSA remains committed to maintaining a sustained supply chain and the procurement of essential medicines and medical supplies, Mr Chingobe reiterated.
